242 related articles for article (PubMed ID: 22780211)
1. Emerging targeted therapies in myelofibrosis.
Barosi G
Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
[TBL] [Abstract][Full Text] [Related]
2. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
3. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
TreliĆski J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
6. Novel therapies for myelofibrosis.
Stein BL; Cervantes F; Giles F; Harrison CN; Verstovsek S
Leuk Lymphoma; 2015; 56(10):2768-78. PubMed ID: 25860240
[TBL] [Abstract][Full Text] [Related]
7. [Molecularly pathogenesis and molecular targeted therapy for myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2015 Feb; 56(2):150-8. PubMed ID: 25765794
[TBL] [Abstract][Full Text] [Related]
8. Advances in the understanding and management of primary myelofibrosis.
Cervantes F; Pereira A
Curr Opin Oncol; 2011 Nov; 23(6):665-71. PubMed ID: 21892083
[TBL] [Abstract][Full Text] [Related]
9. 'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
Assi R; Verstovsek S; Daver N
Curr Opin Hematol; 2017 Mar; 24(2):115-124. PubMed ID: 28072602
[TBL] [Abstract][Full Text] [Related]
10. JAK2 the future: therapeutic strategies for JAK-dependent malignancies.
LaFave LM; Levine RL
Trends Pharmacol Sci; 2012 Nov; 33(11):574-82. PubMed ID: 22995223
[TBL] [Abstract][Full Text] [Related]
11. The future of JAK inhibition in myelofibrosis and beyond.
Mascarenhas JO; Cross NC; Mesa RA
Blood Rev; 2014 Sep; 28(5):189-96. PubMed ID: 25043171
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
13. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
14. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
15. Kinase signaling and targeted therapy for primary myelofibrosis.
Yang Q; Crispino JD; Wen QJ
Exp Hematol; 2017 Apr; 48():32-38. PubMed ID: 28043820
[TBL] [Abstract][Full Text] [Related]
16. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
Lancman G; Mascarenhas J
Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
[TBL] [Abstract][Full Text] [Related]
17. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
[TBL] [Abstract][Full Text] [Related]
18. The use of JAK inhibitors for low-risk myelofibrosis.
Alimam S; McLornan D; Harrison C
Expert Rev Hematol; 2015 Oct; 8(5):551-3. PubMed ID: 26343888
[TBL] [Abstract][Full Text] [Related]
19. The role of cytokines in the initiation and progression of myelofibrosis.
Hasselbalch HC
Cytokine Growth Factor Rev; 2013 Apr; 24(2):133-45. PubMed ID: 23415024
[TBL] [Abstract][Full Text] [Related]
20. Hypothesis: how do JAK2-inhibitors work in myelofibrosis.
Mesa R; Gale RP
Leuk Res; 2009 Sep; 33(9):1156-7. PubMed ID: 19450878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]